Enabling tech continued to assist above-market growth in Q221 with continued demand for spine robotics and navigation systems. New developments in augmented reality, artificial intelligence and smart instruments continue to push the envelope in the spine space.

The WW Spine CAS market, the US Spine Robotics market and the US Spine Navigation market were all up significantly in Q221 according to SmartTRAK Financial Dashboard. Medtronic* (MDT) remained the market leader with > 50% share, followed by Globus* (GMED) and other enabling tech competitors including Brainlab*, DePuy Synthes* (JNJ) and Stryker* (SYK). For detailed Q221 revenues and shares by company in the US, EU and ROW, see the SmartTRAK CAS Spine Financial Dashboard*. 

Among the many topics, including company revenues, market shares, charts and expert analysis, covered in the comprehensive Q221 CAS Spine Market Recap* are:

Robotics continued to help fuel growth in orthopedics in Q221 as new products and companies heat up the market and enabling technologies gain momentum across TJR.

Once again, robotics contributed to revenue growth in the orthopedics market in Q221 and competition continues to heat up with several regulatory clearances and other developments from new market entrants in the quarter. Aside from robotics, enabling technology including intra-operative augmented reality, preoperative planning and navigation reached a number of milestones in Q221 across all indications in total joint replacement.

Among the many topics, including company revenues, market shares, charts and expert analysis, covered in the comprehensive Q221 CAS Ortho Market Recap* are:

SmartTRAK reports that strong sales of spine robotic and enabling technology in Q121 continue to move the ball forward in the adoption curve. Companies are noting an inflection point on the pathway of these technologies becoming mainstream with centers buying multiple robots, and community and university hospitals adopting them.

Among the many topics covered in detail in our comprehensive Q121 CAS Spine Market Recap* are:

Despite an ongoing slowdown in elective procedures due to COVID, enabling technology continued to experience strong demand in orthopedics in Q121. Since the vast majority of patients who put off elective procedures due to the pandemic are expected to come back into the funnel, SmartTRAK anticipates that robotic and other technologies will continue to gain traction well into next year and beyond.

Despite market challenges due to the COVID-19 pandemic, 2020 was a game-changing year for enabling technology for orthopedic surgery with robotics hitting an inflection point in acceptance, with record placements in Q420, and enabling technology across the entire continuum of care making significant inroads.

In Q420, MAKO* robot demand drove much of the 12.3% growth in Stryker’s* US Ortho Other segment. In 2020, MAKO’s installed base grew by 33%, and in Q420 hit a milestone of > 100 system installations at major teaching institutions, ASCs and in competitive accounts in the quarter. In fact, according to the Company, MAKO is now available in ~50% of fellowship programs at teaching institutions in US, as well as some in Europe, which will help the transition to standard of care. Stryker noted that new market entrants (Zimmer Biomet’s* ROSA*, Smith & Nephew’s* CORI* and DePuy Synthes’* VELYS*) have not slowed MAKO momentum.

Among the many topics covered in the comprehensive Q420/FY20 CAS Ortho Market Recap* are:

COVID-19 threw a curveball to spine and orthopedic implant companies in 2020 with the downturn in elective procedures, but one area that continued to make inroads was enabling technologies. Given increasing advances and expanding adoption of these technologies, even during uncertain times, SmartTRAK highlights some significant trends to watch in 2021, including:

1. Flexible Business Models
Companies with robots (Stryker*, MAKO*, Zimmer Biomet*, ROSA*, Smith & Nephew*, NAVIO*/CORI*, Medtronic*, Mazor X*, Globus*, Excelsius GPS) continued to grow at above-market growth in 2020. Record-breaking robotic and navigation system placements in Q3 and Q420 bode well for ...

A post-pandemic recovery appears to be on the horizon in the CAS Spine space.

SmartTRAK highlights what’s new in the Spine and Orthopedic Computer-Assisted Surgery (CAS) markets. Our daily updates cover the latest news and up-to-date intel on competitors, revenues, products, patents, trends and research in CAS. Companies covered include Exactech, DePuy Synthes, THINK Surgical, Subtle Medical, CurvSmith & Nephew, Surgalign, Medtronic and others.

The following is a sampling of market updates covering recently published studies, articles and clinical trials in orthopedic regenerative medicine that were curated, reviewed and posted in real time by Elise Wolf, SmartTRAK’s General Manager, Computer-Assisted Surgery.

Q220 brought unexpected strong demand for orthopedic robotics, despite the COVID-19 pandemic.

Despite the COVID-19 pandemic, Q220 brought in unexpected strong demand for orthopedic robotics. Companies rose to the challenge through flexible business models to accommodate limitations in short-term hospital financial constraints through increased financing and implant volume commitments. The unexpected strength in robotics revenues also demonstrated a rebound in elective (total joint) procedures that is expected to normalize in early 2021.

Among the many topics covered in the comprehensive Q220 CAS Ortho Market Recap* are:

Despite a downturn in the CAS spine market and a decrease in the proportion of robotic spine cases in Q220, interest in spine robotics and other enabling technologies remains strong.

Although robotic system placements and procedures declined in Q220, companies remain optimistic with strong surgeon interest in spine robotics and a long runway ahead given the early stage of adoption and under penetration of the market. Additionally, product enhancements, new applications and the development of surgical platforms that span multiple enabling technologies (robotics, AI, surgical planning, patient-specific implants, etc.) are expected to drive growth in the CAS spine space going forward.

Among the many topics covered in the comprehensive Q220 CAS Spine Market Recap* are: